Details of the Drug Combinations

General Information of This Drug (ID: DM4H7D5)

Drug Name

PHA-767491 DM4H7D5

Synonyms

PHA-767491; 845714-00-3; PHA 767491; CAY10572(PHA-767491); PHA-767491 (CAY10572); 2-Pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one; 1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo[3,2-c]pyridin-4-one; Pyrrolopyridinone, 1; Cdc7/Cdk9 Inhibitor; Kinome_2973; JMC502647 Compound 8; MLS006011036; SCHEMBL4767679; GTPL8763; CHEMBL225519; CTK8F8505; CHEBI:95058; BDBM27344; DTXSID50471069; MolPort-009-019-436; HMS3656P19; HMS3229B21; BCP02855; PHA-767491A; PHA767491; ZINC16052718; s2742; 2651AH; AKOS026674124; SB19465; CS-1208

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PHA-767491 + Panobinostat	DCTASGX	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255-64.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.